

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

ETAS ID: TM562010

| | | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------|-----------------------|-----------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT | | |
| NATURE OF CONVEYANCE: | RELEASE OF SECURITY INTEREST | | |
| CONVEYING PARTY DATA | | | |
| Name | Formerly | Execution Date | Entity Type |
| DEERFIELD PRIVATE DESIGN FUND III, L.P., as Collateral Agent | | 02/13/2020 | Corporation: DELAWARE |
| RECEIVING PARTY DATA | | | |
| Name: | ASSERTIO THERAPEUTICS, INC. (f/k/a DEPOMED, INC.) | | |
| Street Address: | 100 South Saunders Road, Suite 300 | | |
| City: | Lake Forest | | |
| State/Country: | ILLINOIS | | |
| Postal Code: | 60045 | | |
| Entity Type: | Corporation: DELAWARE | | |
| PROPERTY NUMBERS Total: 1 | | | |
| Property Type | Number | Word Mark | |
| Serial Number: | 86937116 | SIMPLESCRIPT | |
| CORRESPONDENCE DATA | | | |
| Fax Number: | 4156932222 | | |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | | | |
| Phone: | 4156932000 | | |
| Email: | crhem@cooley.com | | |
| Correspondent Name: | Cooley LLP | | |
| Address Line 1: | 101 California Street, 5th Floor | | |
| Address Line 4: | San Francisco, CALIFORNIA 94111 | | |
| ATTORNEY DOCKET NUMBER: | 315603-108 | | |
| NAME OF SUBMITTER: | C. Rhem | | |
| SIGNATURE: | /CR/ | | |
| DATE SIGNED: | 02/13/2020 | | |
| Total Attachments: 3 | | | |
| source=Assertio - Depomed 2017 IP Release Executed#page1.tif | | | |
| source=Assertio - Depomed 2017 IP Release Executed#page2.tif | | | |
| source=Assertio - Depomed 2017 IP Release Executed#page3.tif | | | |

CH \$40.00 86937116

RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY

This RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY, dated as of February 13, 2020 (this “Release”), is executed by DEERFIELD PRIVATE DESIGN FUND III, L.P., as Collateral Agent (the “Collateral Agent”), with offices at 780 Third Avenue, 37th Floor, New York, NY 10017, in favor of ASSERTIO THERAPEUTICS, INC. (f/k/a DEPOMED, INC.), a Delaware corporation (the “Pledgor”), with offices at 100 South Saunders Road, Suite 300, Lake Forest, IL 60045, as follows:

W I T N E S S E T H

WHEREAS, pursuant to that certain Grant of Security Interest in Patents and Trademarks, dated as of December 4, 2017 (the “Grant”), executed by the Pledgor in favor of the Collateral Agent, the Pledgor granted to the Collateral Agent a security interest in and to certain collateral (capitalized terms used herein but not otherwise defined shall have the respective meanings given to them in the Grant), including all of its right, title and interest in and to the Trademarks and the Patents set forth on Schedule A attached hereto, and the use thereof, together with all proceeds and products thereof and the goodwill of the business symbolized by the Trademarks (collectively, the “Released Collateral”);

WHEREAS, the Grant was recorded with (i) the Patent Division of the United States Patent and Trademark Office on December 5, 2017 at Reel 044294/Frame 0452 and (ii) the Trademark Division of the United States Patent and Trademark Office on December 5, 2017 at Reel 006225/Frame 0719;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Collateral Agent hereby agrees as follows:

1. The Collateral Agent hereby releases, discharges, cancels and terminates its security interest in and continuing lien on the Released Collateral, including the Patents and Trademarks set forth on Schedule A attached hereto, and re-assigns, re-transfers and re-conveys to Pledgor any and all right, title or interest the Collateral Agent may have in and to the Pledgor’s Released Collateral.
2. The Collateral Agent agrees to execute and deliver such further instruments and take or cause to be taken such other or further action as Pledgor may reasonably request, in order to perfect, confirm or evidence such release, at the sole cost and expense of the Pledgor.
3. The Collateral Agent represents and warrants that it has the full power and authority to execute this Release.
4. The Collateral Agent authorizes and requests the Patent and Trademark Divisions of the United States Patent and Trademark Office, and any other appropriate domestic and foreign authorities as may be necessary or desired by Pledgor, to evidence this Release.


[Signature Page follows]

IN WITNESS WHEREOF, the Collateral Agent, by its duly authorized officer, has executed this Release as of the date first written above.

DEERFIELD PRIVATE DESIGN FUND III, L.P., as
Collateral Agent

By: Deerfield Mgmt III, L.P.
General Partner

By: J.E. Flynn Capital III, LLC
General Partner

By: _____

Name: David J. Clark_____

Title: Authorized Signatory_____

Schedule A

TRADEMARKS AND TRADEMARK APPLICATIONS

| <u>Owner</u> | <u>Mark</u> | <u>Application or Registration No.</u> | <u>Country</u> | <u>Issue or Filing Date</u> |
|---------------|---------------------|--------------------------------------------|----------------|---------------------------------|
| Depomed, Inc. | SimpleScript | 86/937,116 | U.S. | 3/11/2016 |

PATENTS AND PATENT APPLICATIONS

| <u>Owner</u> | <u>Application or Registration No.</u> | <u>Country</u> | <u>Title</u> | <u>Issue or Filing Date</u> |
|---------------|--------------------------------------------|----------------|----------------------------------------------------------------------------------------------------------|---------------------------------|
| Depomed, Inc. | 9,814,705 | U.S. | Intranasal spray device containing pharmaceutical composition | 11/14/2017 |
| Depomed, Inc. | 9,801,816 | U.S. | Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract | 10/31/2017 |
| Depomed, Inc. | 15/421,802 | U.S. | Gastric retentive pharmaceutical compositions for treatment and prevention of CNS disorders | 2/1/2017 |
| Depomed, Inc. | 9,566,258 | U.S. | Gastric retentive pharmaceutical compositions for treatment and prevention of CNS disorders | 2/14/2017 |
| Depomed, Inc. | 15/404,502 | U.S. | Method of Treating Post-Surgical Acute Pain | 1/12/2017 |
| Depomed, Inc. | 15/422,275 | U.S. | Dual Drug Dosage Forms with Improved Separation of Drugs | 2/1/2017 |
| Depomed, Inc. | 15/451,240 | U.S. | Shell-and-Core Dosage form Approaching Zero-Order Drug Release | 3/6/2017 |